<DOC>
	<DOCNO>NCT02602691</DOCNO>
	<brief_summary>Transplant rejection one important complication heart transplantation require specific monitoring , include regular invasive endomyocardial biopsy . The average hospital cost biopsy estimate 3 297 dollar United States . In France , reimbursement rate Health Insurance correspond stay vary 682 25 865 euro , accord find rejection severity . AlloMap® non-invasive blood test identify patient low probability moderate severe acute cell transplant rejection . The non-inferiority use AlloMap® test demonstrate comparison usual care term diagnosis acute cellular rejection randomize study conduct United States . Following study , ISHLT ( International Society Heart Lung Transplantation ) make recommendation advocate use patient 6 month 5 year heart transplantation . This new test could alternative systematic biopsy usually perform patient whose allograft function stable , expensive since analysis blood sample cost 2 000 euros pre-tax France . This cost compare current patient care . By replace biopsy perform systematically , test reduce cost full day hospitalization realization biopsy also cost associate possible complication . In addition , expect use provide benefit patient term quality life . Indeed , achievement biopsy may cause significant stress anxiety patient , due discomfort , pain potential complication may severe . To day , medico-economic assessment conduct prove interest use AlloMap® compare systematic realization endomyocardial biopsy . The purpose CUPIDON study ass effectiveness use AlloMap® test monitor heart transplant patient context usual care accordance international recommendation . AlloMap® use compare current surveillance strategy endomyocardial biopsy 6 month 36 month heart transplantation . The investigator hypothesize use test diagnosis acute cellular transplant rejection would avoid cost large number biopsy , increase quality life patient related health .</brief_summary>
	<brief_title>Cost-utility Analysis AlloMap® Test</brief_title>
	<detailed_description />
	<criteria>Age ≥ 18 year old Heart transplantation since 5 month ( +/ 3 week ) Stable allograft function : Left ventricular ejection fraction ≥ 50 % measure echocardiography No sign presence humoral rejection DSA ( donorspecific antibody ) Absence biopsyproven treat acute cellular rejection previous 3 month Signed consent participate study Patient affiliate social security scheme similar All symptom clinical sign graft failure Treatment transplant rejection ISHLT grade 2R high ( proven biopsy ) previous 3 month Change immunosuppressive molecule previous 30 day Treatment hematopoietic growth factor progress previous 30 day Corticosteroid dose &gt; 20 mg / day prednisone equivalent time inclusion Transfusion previous 30 day Endstage renal failure require renal replacement therapy ( hemodialysis peritoneal dialysis ) Pregnant woman time inclusion Major patient protect law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Heart transplantation</keyword>
	<keyword>AlloMap® gene expression profile test</keyword>
	<keyword>Medico-economic study</keyword>
</DOC>